Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6112557 | 0.81 | KDM4E (0.38) | ATMSMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL31015104 | 0.80 | PTGS1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL21812494 | 0.77 | CTH (0.35) | ALDH1A1 | |
| SCHEMBL31353387 | 0.76 | CA1 (0.33) | — | |
| SCHEMBL26633266 | 0.76 | GBA1 (0.33) | ATMKDM4ELMNARAB9ANPC1 | |
| SCHEMBL16792678 | 0.74 | TSHR (0.35) | GBA1TSHRBACE1 | |
| SCHEMBL15611846 | 0.74 | TSHR (0.33) | KDM4ELMNAADRA2AADRA2BADRA2C | |
| SCHEMBL15248282 | 0.74 | TSHR (0.33) | KDM4ELMNARAB9ANPC1ADRA2A | |
| SCHEMBL15612499 | 0.74 | TSHR (0.36) | SMN1; SMN2KDM4ELMNARAB9ANPC1 | |
| SCHEMBL34472699 | 0.73 | BACE1 (0.34) | KDM4ELMNARAB9ANPC1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121586713-A | Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases | 百济神州(苏州)生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| WO-2025021217-A1 | QUINOLINE DERIVATIVES AND PHARMARCEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-01-30 | — | — | WO | disclosed |
| CN-106414429-B | Pyrazole compounds and their use as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-19 | — | — | US | disclosed |
| US-9932314-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-3152199-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | Actelion Pharmaceuticals Ltd. (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-06 | — | — | US | disclosed |
| WO-2015186056-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | ATM 4238/4885SMN1; SMN2 4020/4885KDM4E 3649/4885 |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | ATM 4238/4885SMN1; SMN2 4020/4885KDM4E 3649/4885 |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | ATM 4238/4885SMN1; SMN2 4020/4885KDM4E 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.